Category: Hutton
-
EF Hutton maintains price target on Enlivex after trial advancement By Investing.com
•
EF Hutton has affirmed its Buy rating on shares of Enlivex Therapeutics (NASDAQ: ), with a $13.00 price target. The firm’s stance comes in light of Enlivex’s recent announcement regarding the progress of its clinical trial for knee osteoarthritis. The Danish Medicines Agency has granted the company permission to start…
-
EF Hutton maintains stock target on GeoVax amid Mpox outbreak By Investing.com
•
On Monday, EF Hutton reiterated its buy rating on shares of GeoVax Labs Inc. (NASDAQ:NASDAQ:) with a hold price target of $18.00. The company’s endorsement comes as GeoVax is actively developing the Modified Vaccinia Ankara (MVA) vaccine to combat the outbreak of smallpox virus type 1 in the Democratic Republic…